Dynavax Technologies Corp
DVAX10.860USD
0.0000.00%
收盘 08/01, 16:00（美东）报价延迟15分钟
1.34B总市值
亏损市盈率 TTM
关于 Dynavax Technologies Corp 公司
Dynavax Technologies Corporation 是一家商业阶段生物制药公司，致力于开发和商业化疫苗。该公司的产品包括 HEPLISAV-B 乙肝疫苗和 CpG 1018。其 HEPLISAV-B（重组）（佐剂）用于预防 18 岁及以上成人中所有已知乙肝病毒亚型引起的感染。HEPLISAV-B 是一种两剂成人乙肝疫苗。该公司还生产和销售 CpG 1018 佐剂，即 HEPLISAV-B 中使用的佐剂。该公司还致力于开发利用 CpG 1018 佐剂的多项目临床管线，以开发针对未满足医疗需求的适应症的改良疫苗。其管线项目包括正在开发的带状疱疹、破伤风、白喉和百日咳 (Tdap) 和鼠疫的候选疫苗。其带状疱疹疫苗项目 Z-1018 是一种正在开发的用于预防 50 岁成人带状疱疹的试验性候选疫苗及以上。
公司简介
公司代码DVAX
公司名称Dynavax Technologies Corp
上市日期Feb 19, 2004
CEOMr. Ryan Spencer
员工数量405
证券类型Ordinary Share
年结日Feb 19
公司地址2100 Powell Street
城市EMERYVILLE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94608
电话15108485100
网址https://www.dynavax.com/
公司代码DVAX
上市日期Feb 19, 2004
CEOMr. Ryan Spencer
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
277.67K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. David F. Novack
Mr. David F. Novack
President, Chief Operating Officer
President, Chief Operating Officer
56.05K
+33.36%
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
31.42K
--
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+23.89%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
25.52K
--
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+30.19%
Dr. Daniel L. (Dan) Kisner, M.D.
Dr. Daniel L. (Dan) Kisner, M.D.
Independent Director
Independent Director
23.33K
+32.77%
Mr. Brent MacGregor
Mr. Brent MacGregor
Independent Director
Independent Director
21.83K
+35.83%
Dr. Emilio Emini
Dr. Emilio Emini
Independent Director
Independent Director
1.44K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
277.67K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. David F. Novack
Mr. David F. Novack
President, Chief Operating Officer
President, Chief Operating Officer
56.05K
+33.36%
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
31.42K
--
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+23.89%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
25.52K
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
业务USD
名称
营收
占比
HEPLISAV-B
64.96M
95.30%
Other revenue
3.21M
4.70%
地区USD
名称
营收
占比
US
67.81M
99.47%
Non-US
358.00K
0.53%
业务
地区
业务USD
名称
营收
占比
HEPLISAV-B
64.96M
95.30%
Other revenue
3.21M
4.70%
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
15.53%
Deep Track Capital LP
14.82%
The Vanguard Group, Inc.
7.22%
State Street Global Advisors (US)
5.65%
Tang Capital Management, LLC
4.79%
Other
51.99%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
15.53%
Deep Track Capital LP
14.82%
The Vanguard Group, Inc.
7.22%
State Street Global Advisors (US)
5.65%
Tang Capital Management, LLC
4.79%
Other
51.99%
股东类型
持股股东
占比
Investment Advisor
40.52%
Hedge Fund
38.07%
Investment Advisor/Hedge Fund
21.73%
Research Firm
5.56%
Pension Fund
1.34%
Individual Investor
0.59%
Sovereign Wealth Fund
0.57%
Bank and Trust
0.55%
Venture Capital
0.06%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
551
130.99M
109.09%
-16.02M
2025Q1
575
132.57M
110.30%
-15.70M
2024Q4
565
133.92M
107.04%
-18.98M
2024Q3
561
132.88M
101.45%
-18.82M
2024Q2
547
135.21M
103.33%
-14.69M
2024Q1
545
136.49M
104.51%
-4.07M
2023Q4
529
128.50M
99.42%
-9.47M
2023Q3
515
128.65M
99.89%
-9.14M
2023Q2
503
129.32M
100.65%
-12.27M
2023Q1
497
129.65M
101.54%
-1.28M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
18.65M
15.53%
-799.41K
-4.11%
Mar 31, 2025
Deep Track Capital LP
17.79M
14.82%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
8.67M
7.22%
-459.90K
-5.04%
Mar 31, 2025
State Street Global Advisors (US)
6.79M
5.65%
-1.00M
-12.88%
Mar 31, 2025
Tang Capital Management, LLC
5.75M
4.79%
+3.90M
+210.81%
Mar 31, 2025
Chicago Capital, LLC
5.34M
4.45%
-36.81K
-0.68%
Mar 31, 2025
Deerfield Management Company, L.P.
5.19M
4.32%
-2.33K
-0.04%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
4.01M
3.34%
-58.27K
-1.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.07M
2.55%
+71.47K
+2.39%
Mar 31, 2025
Renaissance Technologies LLC
2.71M
2.25%
+350.25K
+14.87%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco Biotechnology & Genome ETF
2.7%
Virtus LifeSci Biotech Products ETF
1.84%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.15%
ETC 6 Meridian Small Cap Equity ETF
0.79%
Invesco S&P SmallCap Health Care ETF
0.79%
Franklin Genomic Advancements ETF
0.64%
Themes US Small Cap Cash Flow Champions ETF
0.45%
SPDR S&P Biotech ETF
0.41%
Royce Quant Small-Cap Quality Value ETF
0.32%
ETC 6 Meridian Low Beta Equity Strategy ETF
0.29%
查看更多
Invesco Biotechnology & Genome ETF
占比2.7%
Virtus LifeSci Biotech Products ETF
占比1.84%
Pacer US Small Cap Cash Cows Growth Leaders ETF
占比1.15%
ETC 6 Meridian Small Cap Equity ETF
占比0.79%
Invesco S&P SmallCap Health Care ETF
占比0.79%
Franklin Genomic Advancements ETF
占比0.64%
Themes US Small Cap Cash Flow Champions ETF
占比0.45%
SPDR S&P Biotech ETF
占比0.41%
Royce Quant Small-Cap Quality Value ETF
占比0.32%
ETC 6 Meridian Low Beta Equity Strategy ETF
占比0.29%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
